Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 16;20(5):30.
doi: 10.1007/s11926-018-0729-1.

Functional Defects of Treg Cells: New Targets in Rheumatic Diseases, Including Ankylosing Spondylitis

Jinlin Miao  1 , Ping Zhu  2
Affiliations
Review

Functional Defects of Treg Cells: New Targets in Rheumatic Diseases, Including Ankylosing Spondylitis

Jinlin Miao et al. Curr Rheumatol Rep. .

Abstract

Purpose of review: This study aims to review the advances of Treg cell biology, the functional defects of Treg cells, and the potential strategies for the experimental, preclinical or clinical application of Treg cell therapy in the context of autoimmune/immune-mediated rheumatic diseases.

Recent findings: CD4+CD25+ regulatory T (Treg) cells are a phenotypically and functionally heterogeneous subset of lymphocytes that prevent a variety of autoimmune diseases. As in many autoimmune diseases, the functional defects of Treg cells are supposed to play relevant roles in the pathogenesis and development of systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, and other autoimmune/immune-mediated rheumatic diseases. Consequently, manipulation and modulation of Treg cells represent a potent strategy for therapeutic benefit in many such diseases. A further understanding of the functional defects of Treg cells in rheumatic diseases will contribute to find new targets and therapies in rheumatic diseases, including ankylosing spondylitis.

Keywords: Ankylosing spondylitis; Autoimmune diseases; Forkhead box P3; Immunotherapy; Regulatory T cells; Rheumatol arthritis.

PubMed Disclaimer

References

    1. J Exp Med. 2007 Jul 9;204(7):1543-51 - PubMed
    1. Sci Transl Med. 2011 May 18;3(83):83ra41 - PubMed
    1. Int J Rheum Dis. 2016 Feb;19(2):167-71 - PubMed
    1. Scand J Rheumatol. 2007 Nov-Dec;36(6):428-33 - PubMed
    1. Rev Bras Reumatol. 2014 May-Jun;54(3):241-6 - PubMed

MeSH terms

LinkOut - more resources